Title: Establishes a $25 Cap on Insulin Prices
Signed by Governor Ned Lamont
Title: Establishes a $25 Cap on Insulin Prices
Vote to pass a bill that establishes a $25 cap on the price of insulin.
Requires the health commissioner, by November 1, 2020, to establish a working group to determine whether diabetic patients should be referred to a federally-qualified health center (Sec. 1).
Requires the working group to meet before January 11, 2021 (Sec. 1).
Requires the working group to submit their recommendation for diabetic patients to a federally-qualified health center by May 1, 2021 (Sec. 1).
Authorizes pharmacists to immediately prescribe a 30-day supply of insulin or any other diabetic device to patients under the following circumstances (Sec. 3):
The patient has less than a 7-day supply of insulin;
The pharmacist determines the patient is in grave physical danger if they do not receive an adequate supply of insulin within 7 days; or
The patient has not recently received a prescription for insulin.
Requires Section 3 to take effect on January 1, 2021 (Sec. 3).
Prohibits insulin and glucagon drug costs from exceeding $25 for a 30-day supply (Sec. 13).
Prohibits the cost of diabetic and ketoacidosis devices from exceeding $100 for a 30-day supply (Sec. 13).
Requires Section 13 to take effect on January 1, 2022 (Sec. 13).
Requires group health insurance policies to provide coverage for the treatment of all types of diabetes, including (Sec. 14):
Laboratory and diagnostic tests;
Insulin and non-insulin drugs;
Diabetic-related devices; and
Diabetic ketoacidosis devices.
Requires Section 14 to take effect on January 1, 2022 (Sec. 14).
Title: Establishes a $25 Cap on Insulin Prices
Vote to pass a bill that establishes a $25 cap on the price of insulin.
Requires the health commissioner, by November 1, 2020, to establish a working group to determine whether diabetic patients should be referred to a federally-qualified health center (Sec. 1).
Requires the working group to meet before January 11, 2021 (Sec. 1).
Requires the working group to submit their recommendation for diabetic patients to a federally-qualified health center by May 1, 2021 (Sec. 1).
Authorizes pharmacists to immediately prescribe a 30-day supply of insulin or any other diabetic device to patients under the following circumstances (Sec. 3):
The patient has less than a 7-day supply of insulin;
The pharmacist determines the patient is in grave physical danger if they do not receive an adequate supply of insulin within 7 days; or
The patient has not recently received a prescription for insulin.
Requires Section 3 to take effect on January 1, 2021 (Sec. 3).
Prohibits insulin and glucagon drug costs from exceeding $25 for a 30-day supply (Sec. 13).
Prohibits the cost of diabetic and ketoacidosis devices from exceeding $100 for a 30-day supply (Sec. 13).
Requires Section 13 to take effect on January 1, 2022 (Sec. 13).
Requires group health insurance policies to provide coverage for the treatment of all types of diabetes, including (Sec. 14):
Laboratory and diagnostic tests;
Insulin and non-insulin drugs;
Diabetic-related devices; and
Diabetic ketoacidosis devices.
Requires Section 14 to take effect on January 1, 2022 (Sec. 14).
Title: Establishes a $25 Cap on Insulin Prices